Latest News

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

PHILADELPHIA–(BUSINESS WIRE)—- $MDCO #ASCVD–The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA (small-interfering RNA) class. In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary effica

Source link

Related posts

UCI study finds new cause of cerebral microbleeds


#Ohio #Doctors Are Still #Overprescribing #Opioids Despite #PublicHealthEmergenc…


Engineered probiotic strain of Escherichia coli bacteria can reverse dangerously high levels of blood ammonia


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy